EyePoint Pharmaceuticals has been granted a patent for compositions containing multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists for treating angiogenesis-related conditions. The patent also covers a method involving administering an antibody to treat ocular conditions by activating Tie2 and inhibiting VEGF function. GlobalData’s report on EyePoint Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights EyePoint Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on EyePoint Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. EyePoint Pharmaceuticals's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of ocular conditions with multi-specific compounds

Source: United States Patent and Trademark Office (USPTO). Credit: EyePoint Pharmaceuticals Inc

A recently granted patent (Publication Number: US11873334B2) discloses a method for treating various ocular conditions in a subject by administering a specific antibody. The antibody comprises a first domain that activates Tie2 and a second domain that binds to and inhibits the function of VEGF. This method is particularly useful for treating conditions such as diabetic retinopathy, neovascularization, vascular leak, increased intraocular pressure, ocular edema, diabetic macular edema, wet age-related macular degeneration, ocular inflammation, and retinal vein occlusion.

The method allows for the administration of the antibody through various routes such as intravitreal, subcutaneous, or systemic, with the therapeutically effective amount ranging from about 0.25 mg to 200 mg. Additionally, the patent specifies that the subject being treated is a human, and the therapeutically effective amount can vary from about 1 mg/kg to 10 mg/kg or from about 1 mg to 50 mg, depending on the specific ocular condition being targeted. This patent highlights a novel approach to treating ocular conditions by targeting both Tie2 activation and VEGF inhibition, offering potential benefits for patients suffering from a range of eye-related issues.

To know more about GlobalData’s detailed insights on EyePoint Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies